Sign inCreate account

Report workspace tools

NCT04123392UNKNOWNanonymous

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor

Source record

Nanfang Hospital, Southern Medical University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Indication / condition

AI-normalized

TP53

Intervention

Source record

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Source & freshness

Source record

NCT ID

NCT04123392

Original source

ClinicalTrials.gov

Source last updated

Oct 10, 2019

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04123392

Title

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor

Nanfang Hospital, Southern Medical University

Status

UNKNOWN

Phase

PHASE2

Condition raw

TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation

Condition normalized

TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Target normalized

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Interventions

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Public preview

Source record

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation is a PHASE2 clinical asset sponsored by Nanfang Hospital, Southern Medical University in TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation. SEO and diligence focus: Decitabine, Busulfan (BU), Cyclophosphamide (CY), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04123392

Status

UNKNOWN

Phase

PHASE2

Sponsor

Nanfang Hospital, Southern Medical University

Executive brief

Investment-Ready Snapshot

Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allogeneic Hematopoietic Stem Cell Transplantation is a PHASE2 clinical asset sponsored by Nanfang Hospital, Southern Medical University in TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation. SEO and diligence focus: Decitabine, Busulfan (BU), Cyclophosphamide (CY), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 10, 2019
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04123392

Indication

TP53

Modality

small molecule

Target

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Intervention

Decitabine, Busulfan (BU), Cyclophosphamide (CY)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.